BWA
MYGN icon

Basecamp Wealth Advisors’s Myriad Genetics MYGN Stock Holding History

Basecamp Wealth Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01K Buy
177
+138
+354% +$626 ﹤0.01% 1518
2026
Q1 		$176 Buy
+39
New +$203 ﹤0.01% 1884

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Basecamp Wealth Advisors's MYGN Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Myriad Genetics (MYGN) stake by 354% in Q2 2026, buying an estimated $626 and bringing the position to 177 shares worth $1.01K. The position accounts for ﹤0.01% of the portfolio, ranked #1518.

Basecamp Wealth Advisors first reported a position in MYGN in Q1 2026 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Basecamp Wealth Advisors held 177 shares of Myriad Genetics worth $1.01K as of Q2 2026.
  • Basecamp Wealth Advisors bought 138 Myriad Genetics shares in Q2 2026, an estimated $626.
  • Myriad Genetics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1518 holding.
  • Basecamp Wealth Advisors first reported a position in Myriad Genetics in Q1 2026 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.